Methods for multiplexed drug evaluation
Patent Information
- Authority / Receiving Office
- US ยท United States
- Current Assignee / Owner
- PRESAGE BIOSCI
- Publication Date
- 2014-06-19
- Estimated Expiration
- Not applicable ยท inactive patent
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
CROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 61 / 725,978, filed Nov. 13, 2012, which application is incorporated herein by reference.BACKGROUND
[0002] Numerous cancer-related therapeutics are under preclinical, phase I or phase II clinical trial and evaluations at any particular time; however, most of them will fail to advance. In fact, numerous drug candidates fail in the preclinical test, and it is estimated that more than 90% of cancer-related therapeutics will fail phase I or II clinical trial evaluation. The failure rate in phase III trials is almost 50%, and the cost of new drug development from discovery through phase III trials is between $0.8 billion and $1.7 billion and can take between eight and ten years.
[0003] In addition, many subjects fail to respond even to standard drugs that have been shown to be efficacious. Excessive systemic concentrations can be maintained for many oncology drug candidates in efforts to achieve a desi...